263 related articles for article (PubMed ID: 37373535)
1. Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Frerker B; Bock F; Cappel ML; Kriesen S; Klautke G; Hildebrandt G; Manda K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373535
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
4. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Kuebler JP; de Gramont A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
[TBL] [Abstract][Full Text] [Related]
6. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Kim GP; Sargent DJ; Mahoney MR; Rowland KM; Philip PA; Mitchell E; Mathews AP; Fitch TR; Goldberg RM; Alberts SR; Pitot HC
J Clin Oncol; 2009 Jun; 27(17):2848-54. PubMed ID: 19380443
[TBL] [Abstract][Full Text] [Related]
7. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Tournigand C; André T; Achille E; Lledo G; Flesh M; Mery-Mignard D; Quinaux E; Couteau C; Buyse M; Ganem G; Landi B; Colin P; Louvet C; de Gramont A
J Clin Oncol; 2004 Jan; 22(2):229-37. PubMed ID: 14657227
[TBL] [Abstract][Full Text] [Related]
9. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of oxaliplatin in the management of colorectal cancer.
de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
[TBL] [Abstract][Full Text] [Related]
13. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Rougier P; Lepille D; Bennouna J; Marre A; Ducreux M; Mignot L; Hua A; Méry-Mignard D
Ann Oncol; 2002 Oct; 13(10):1558-67. PubMed ID: 12377643
[TBL] [Abstract][Full Text] [Related]
14. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
15. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
[TBL] [Abstract][Full Text] [Related]
18. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
[TBL] [Abstract][Full Text] [Related]
19. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Cunningham D; Sirohi B; Pluzanska A; Utracka-Hutka B; Zaluski J; Glynne-Jones R; Koralewski P; Bridgewater J; Mainwaring P; Wasan H; Wang JY; Szczylik C; Clingan P; Chan RT; Tabah-Fisch I; Cassidy J
Ann Oncol; 2009 Feb; 20(2):244-50. PubMed ID: 18854549
[TBL] [Abstract][Full Text] [Related]
20. FDA drug approval summaries: oxaliplatin.
Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
